17-beta-hydroxysteroid dehydrogenase deficiency: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 13: | Line 13: | ||
MeshID = | | MeshID = | | ||
}} | }} | ||
{{17-beta-hydroxysteroid dehydrogenase deficiency }} | {{17-beta-hydroxysteroid dehydrogenase 3 deficiency }} | ||
{{CMG}}; {{AE}}{{Abdulkerim}} | {{CMG}}; {{AE}}{{Abdulkerim}} | ||
Revision as of 06:08, 6 January 2022
| congenital adrenal hyperplasia due to CYP17A1 deficiencies | |
| OMIM | 264300 |
|---|---|
| DiseasesDB | 32638 |
Template:17-beta-hydroxysteroid dehydrogenase 3 deficiency Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdulkerim Yassin, M.B.B.S[2]
Synonyms and keywords: HSD17B10 deficiency; HSD10 deficiency; 3-hydroxyacyl-CoA dehydrogenase II deficiency; 2-methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency; MHBD deficiency
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating 17-beta-hydroxysteroid dehydrogenase deficiency from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Molecular Genetic Studies | Genotyping | Pelvic X Ray | CT | Ultrasound | Other Imaging Findings | Other Diagnostic Studies
Treatment
Medical Therapy | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies